703 posters,  63 sessions,  7 topics,  1978 authors 
ePostersLive® by SciGen® Technologies S.A. All rights reserved.

5714
Gender Differences in Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for Treatment of Acute Moderate-to-Severe Pain
Session: MP-04b
Thurs, April 19, 3:30-5:00 pm
Uris (Shubert Complex), 6th floor

Please note, medically challenging cases are removed three months after the meeting and scientific abstracts after three years.

Rate

No votes yet

 Gender Differences in Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for Treatment of Acute Moderate-to-Severe Pain

 

The Sufentanil Sublingual Tablet 30 mcg (SST 30 mcg; DSUVIA™) is a analgesic product-candidate currently in development for management of moderate-to-severe acute pain in medically supervised settings such as short-stay surgery or the emergency department (ED). The SST 30 mcg late-phase clinical program was partially sponsored by the U.S. Department of Defense and included four trials; two randomized and placebo-controlled and two open-label.  SST 30 mcg is dispensed by an HCP via pre-filled applicator and appears well-suited for short duration acute pain management because it acts rapidly (plasma-CNS equilibration time of 6 minutes), does not require an invasive route of delivery and possesses a predictable off-set, in part due to lack of active metabolites.1 The primary objective of this analysis was to examine the efficacy and integrated safety results by sex across all clinical trials conducted in ambulatory surgery and emergency medicine settings. 

Enter Poster ID (e.gGoNextPreviousCurrent